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The performance of antigen galactomannan (GM) for diagnosing invasive aspergillosis
(IA) is hampered by the occurrence of false-positive results. Quantitative PCR has
been proposed to improve the diagnosis of IA. Therefore, we analyzed the value of
performing a PCR test to the GM-positive serum sample. Using a quantitative PCR
assay specific for Aspergillus fumigatus 28S ribosomal DNA, we retrospectively tested
422 GM-positive (Platelia Bio-Rad kit) serum samples collected over 1 year from 147
patients. The cases were classified based on EORTC criteria as “proven,” “probable,”
and “no–IA” before availability of the PCR results. After exclusion of 65 samples for non-
reproducibility of GM positivity (n = 62) or PCR inhibition (n = 3), 75 (21.0%) of the
remaining 357 samples were PCR-positive. GM and fungal DNA showed a significantly
positive correlation (p < 0.0001, R2 = 0.27, slope = 0.98 ± 0.19). At least one PCR-
positive result was observed in 63.3% (31/49) of IA patients and in 13.2% (13/98) of
non-IA patients (p < 0.0001). The PCR positivity was also associated with the presence
of other microbiological criteria among the 44 patients with IA and complete mycological
workup (p = 0.014), as well as a higher mortality rate at six months among the 135
patients with hematological conditions (p = 0.0198). Overall, we found a quantitative
correlation between serum GM and circulating DNA with an increased likelihood of IA
when both were positive. A PCR-positive result also supported a higher fungal load
when GM was already positive. We advocate adding a PCR test for every confirmed
GM-positive serum sample.
Keywords: Aspergillus fumigatus, invasive aspergillosis, galactomannan, quantitative real-time PCR, circulating
DNA
INTRODUCTION
The diagnosis of probable and proven invasive aspergillosis (IA) requires microbiological criteria,
which include the galactomannan (GM) antigen (De Pauw et al., 2008). This antigen is produced
by several molds including Aspergillus fumigatus, the main species responsible for IA (Lortholary
et al., 2011). For serum, the test is mainly used as a screening test to initiate a diagnostic workup
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or to start antifungal therapy as soon as possible (Marchetti
et al., 2012). However, concern has always been raised about
the rate of false positivity using the Platelia Aspergillus Ag assay
(Bio-Rad Laboratories, Marnes la Coquette, France) (Marchetti
et al., 2012). We recently showed the importance of excluding
unreproducible positive results by testing GM-positive samples
twice (Guigue et al., 2015). However, numerous GM-positive
samples cannot be ascribed to IA even after an intensive
diagnostic work-up including imaging and mycology with direct
examination and culture. At a cut-off value 0.5 ODI and an IA
prevalence of 8%, a meta-analysis showed 19% of false positives
(Leeflang et al., 2008).
Real-time quantitative PCR assays have been proposed to
improve the diagnosis of IA. With the advent of PCR, several
technical procedures have been recommended for testing serum
(White et al., 2011). With such improvements, PCR should
be recommended for diagnosing IA (White et al., 2015). The
combination of both tests to improve the clinical utility for the
diagnosis of IA has been advocated for many years (Bretagne
et al., 1998; Barnes et al., 2013). In a recent meta-analysis,
the association of positive results for both tests was highly
suggestive of an active infection with a positive predictive value
of 88% (Arvanitis et al., 2015). However, a screening strategy
utilizing twice weekly GM and PCR testing is questioned with the
generalization of anti-mold prophylaxis (Patterson et al., 2016).
In decreasing the prevalence of IA, the efficiency of the screening
strategy decreases (Leeflang et al., 2008). In these conditions, GM
testing is integrated in a diagnostic work-up without the previous
serial tests to interpret the results. Thus, a positive GM results
should be interpreted on a single result. One possibility is to ask
for a second serum sample. However, this can delay the initiation
of an appropriate therapy. We wondered whether adding a PCR
test for every GM-positive sample without waiting for additional
samples could improve the diagnosis of IA.
MATERIALS AND METHODS
Ethics Statement
The present study was a non-interventional retrospective study
performed using biological material and clinical data obtained for
standard diagnostics without any supplementary sampling and
no change in the usual procedures. French Public Health Law
(CSP Art L1121-1.1) does not require specific approval from an
ethics committee for this study which is exempted from specific
informed consent application.
Serum Samples Collection and GM
Detection
From January 1st, 2013 to December 31st, 2013, 7628 serum
samples were tested using the Platelia Bio-Rad kit mainly
as part of the screening of 1374 patients at risk of IA
according to previous recommendations (Marchetti et al., 2012).
GM detection was performed according to the manufacturer’s
instructions. The results were inferred from the ratio of the
optical density (OD) results from the sample and the controls
and are expressed as GM-OD index (GM-ODI). For each positive
serum sample (GM-ODI > 0.5), another test on the same serum
sample was performed the next day as part of our routine practice
(Guigue et al., 2015). Only the samples that tested positive twice
were considered as positive, and the mean of the two GM-ODIs
was used for further analyses. The serum samples that turned
negative were considered as unreproducible results (Guigue et al.,
2015). The serum samples were stored at −80◦C until further
analysis.
DNA Detection
All serum samples tested positive with more than 1 ml available
were analyzed. Storage at −80◦C before PCR did not exceed
2 years. After thawing, DNA from 1 mL of serum was extracted
using the Qiasymphony DSP virus/Pathogen Mini kit (Qiagen)
and a Qiasymphony apparatus (Qiagen), eluted in 85 µL, and
tested in duplicate using the 28S rDNA PCR assay previously
reported (Challier et al., 2004). Primer and probe concentrations
were set at 0.3 and 0.1 µM in the 480 probe Master (Roche),
respectively, and the PCR assay was performed in a LightCycler
480 instrument (Roche).
The results were expressed in quantification cycles (Cq),
with higher values indicating less targeted DNA in the sample.
Positivity was defined by at least one of the two duplicates having
Cq ≤ 45 cycles. The mean value of the duplicates was retained
for further comparisons when both were positive and the single
value when one replicate was positive alone. DNA extraction and
amplification yields were assessed using the Simplexa Extraction
and Amplification Control Set (Focus Diagnostics, Cypress, CA,
United States) as an internal control (IC). The PCR assay was
performed blind to interpretation of the GM results (true or false
positives) and to the clinical classification.
Mycology Laboratory Result
Respiratory specimens [bronchoalveolar lavage (BAL) fluid,
induced sputum, sputum] were split into two parts. One part
underwent direct examination using microscopy after staining
with calcofluor (BD Biosciences) in KOH (10%). The other
part was seeded on Sabouraud dextrose agar with gentamycin
and chloramphenicol (Bio-Rad) and incubated at 30 and
37◦C. Every positive culture was identified using phenotypic
methods. Molecular identification was done based on sequencing
three different loci (Internal Transcribed Spacer, beta-tubulin,
calmodulin). Sequences were then posted in the Mycobank
database1 and Institut Pasteur FungiBank2.
Patient Classification
Every four months, a local multidisciplinary medical committee
analyses each effective anti-mold therapy recorded in the
pharmacy department and classifies the patients as ‘proven,’
‘probable,’ IA, or ‘no-IA’ according to criteria from the European
Organization for Research and Treatment of Cancer and from the
Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) (De Pauw et al., 2008). For patients without
1http://www.mycobank.org/BioloMICSSequences.aspx?expandparm=f&file=all
2http://fungibank.pasteur.fr/
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FIGURE 1 | Results of the duplicates performed for each PCR-positive
sample. The positive duplicates (+/+) had lower mean Cq values than the
sample (+/–) with only one duplicate positive (t-test; p < 0.001).
hematological condition or solid organ transplantation not
responding to the EORTC/MSG definition, ad hoc classification
was consensually performed by the local committee. The patient
outcome was censored at 6 months (183 days).
Graphs and Statistical Analysis
Chi-2 test and Fisher’s exact test were used for contingency tables
analyses for calculation of statistical association. The potential
relationship between GM and Cq was studied using linear
regression and for comparison of slopes, a P-value (two-tailed)
testing the null hypothesis that the slopes are all identical (the
lines are parallel) was calculated. Survivals were determined by
Kaplan–Meier method and compared by the Mantel–Cox test.
For comparisons of quantitative data, we performed unpaired
two-tailed t-test for normally distributed data. P-values of
<0.05 were considered significant. All analyses and graphs were
performed using Prism software v.6.0 (Graphpad).
RESULTS
Of the 422 GM-positive serum samples tested by PCR, three
were excluded because of IC amplification failure. Among
the 419 remaining samples, 62 were unreproducible GM-
positive samples, i.e., the first positive result (median ODI: 0.75,
interquartile range: 0.55–1.005) tested negative upon retesting.
All were PCR-negative. These 62 samples were from 53 patients
(median number 1; interquartile range 1–1 range 1–3). None of
these patients developed IA.
The remaining 357 samples were confirmed to be true GM-
positive samples after retesting (median difference: ODI 0.11
interquartile range [0.04–0.22], mean± SD 0.19± 0.27). Among
these, 75 (21.0%) were PCR-positive with a median of one positive
sample per patient [interquartile range 1–2; range 1–13]. For
the duplicates, they were more consistently both positive when
the Cq was below 38 (Figure 1). When looking at quantitative
values of the assays, the GM-ODI and the Cq showed an
inversely significant correlation (slope=−0.98± 0.19, R2= 0.27;
p < 0.0001). When considering PCR results from samples
collected before or during antifungal therapy, the correlation was
significantly improved (p= 0.019) for the samples before therapy
(n= 28, slope=−1.5± 0.29, R2 = 0.50; p < 0.0001) compared to
those collected after the initiation of antifungal treatment (n= 47,
slope=−0.61± 0.23, R2 = 0.13; p= 0.01) (Figure 2).
The 357 GM-positive samples (median 1; range 1–17 samples
per patient) were from 147 patients with mainly hematological
diseases as an underlying condition (Table 1), of whom 49
(33.4%) were classified as having IA (47 with probable IA, 2 with
proven IA) and the remaining 98 (66.7%) as not having probable
or proven IA (Table 1). At least one PCR-positive serum sample
was observed in 31 (63.3%) of the 49 patients with IA, including
the two proven cases, and in 13 (13.2%) of the 98 patients without
IA (p < 0.0001) (Table 1). Notably, none of the 10 patients
with common variable immunodeficiency disease (CIVD) were
considered as having IA and all were PCR-negative (Table 1).
Among the 18 patients with IA who were PCR-negative,
one patient (five samples) had probable IA due to Emericella
quadrilineata, and one patient (one sample) had probable IA
due to A. flavus, based on culture results. Both species were not
detected by our PCR assay. Among the 98 patients without IA
who were GM-positive, one (one sample) had cryptococcosis and
one (three samples) had histoplasmosis. Among the remaining 96
patients, who were GM-positive, 18 (18.75%) were given effective
anti-mold therapy and 12 (66.7%) of them were PCR-positive, in
contrast with only one (1.3%) PCR-positive patient among the
77 GM-positive patients who were not given effective anti-mold
therapy (p < 0.0001) (Table 1).
Among the 49 patients with IA, 44 had other investigations
performed (direct microscopic examination, culture, BAL GM
testing). Among these 44 patients, the percentage of PCR-positive
patients increased with the number of other positive criteria,
from 36.8% (7/19) with GM positivity alone to 76.9% (19/25)
when GM, culture and/or BAL GM was positive (p = 0.014)
(Table 2).
We also analyzed the survival of the patients for whom
a 6-month follow up was available (n = 135) and who had
underlying hematological diseases or allogeneic hematopoietic
stem cell transplantation to avoid confusion with the other
underlying diseases (Figures 3A–C). Survival was significantly
lower (p = 0.001) in PCR-positive patients compared to PCR-
negative patients (Figure 3A). We further analyzed the data
according to the presence or not of the EORTC/MSG 2008
criteria (Figure 3B). The patients without EORTC/MSG criteria
had a better survival (p < 0.001) whatever the PCR result than
patients who fulfilled the EORTC/MSG criteria who exhibited the
worst prognosis when PCR was positive, even if the difference
between PCR-negative and PCR-positive patients did not reach
significance (p = 0.073). When analyzing the quantitative results
(n = 38 patients), the patients with a Cq < 36 on the first
PCR-positive sample had a shorter survival than patient with a
Cq > 36 (p= 0.028) (Figure 3C). The Cq values of the first PCR-
positive sample were significantly lower (t-test, p= 0.0066) in the
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FIGURE 2 | Correlation between galactomannan index (GM-ODI) and quantification cycle (Cq) of Aspergillus fumigatus PCR assay in GM-positive serum samples
obtained before (A) or after (B) initiation of antifungal therapy.
TABLE 1 | Underlying disease or risk factors of invasive fungal diseases of the 147 adults patients with the PCR results of the 357 true GM-positive samples tested, and
the results according to the final diagnosis of invasive aspergillosis (IA).
Underlying diseases or
condition
Number of
patients
(n = 147)
Number of
samples
(n = 357)
Number of PCR
samples
(n = 75)
Number of IA
patients
(n = 49)
Number of PCR-positive
IA patients (n = 31)
Number of treated
patients wo IA
diagnosis (n = 18)
Myeloid disorders 26 (17.7) 49 [1–6] 14 (28.6) 7 (26.9) 5 (71.4) 5 (28)
Acute myeloid leukemia 22 (15) 39 [1–5] 9 (23.1) 4 (18.2) 4 (100) 3 (17)
Myelodysplasia 4 (2.7) 10 [1–6] 5 (50) 3 (75) 1 (33.3) 2 (11)
Acute lymphoid leukemia 13 (8.8) 26 [1–6] 5 (19.2) 3 (23.1) 2 (66.7) 5 (28)
Chronic lymphoproliferative
disorders
39 (26.5) 76 [1–7] 18 (23.7) 22 (56.4) 11 (50) 4 (23)
Lymphoma 26 (17.7) 50 [1–7] 11 (22) 14 (53.8) 7 (50) 3 (17)
Multiple myeloma 11 (7.5) 21 [1–7] 6 (28.6) 6 (54.5) 3 (50) 1 (6)
Chronic lymphoid leukemia 2 (1.4) 5 [1–4] 1 (20) 2 (100) 1 (50) 0 (0)
Allogeneic stem cell
transplantationa
42 (28.6) 153 [1–17] 29 (19) 11 (26.2) 8 (72.7) 2 (11)
Renal transplantation 6 (4.1) 15 [1–5] 6 (40) 3 (50) 2 (66.7) 1 (6)
CVIDb 10 (6.8) 17 [1–5] 0 (0) 0 (0) 0 (0) 1 (6)
AIDS 6 (4.1) 8 [1–3] 1 (12.5) 1 (16.7) 1 (100) 0 (0)
Othersc 5 (3.4) 13 [1–5] 2 (15.4) 2 (40) 2 (100) 0 (0)
Numbers in () represent % and numbers in [] represent range/patient; wo, without.
aUnderlying diseases include myeloid disorders (n = 18), acute lymphoid leukemia (n = 7), chronic lymphoproliferative disorders (n = 16), and sickle cell disease (n = 1).
bCommon variable immunodeficiency disease.
c Includes: pulmonary carcinoma (n = 2); amyloidosis (n = 1); Still disease (n = 1); Intensive care unit (n = 1).
The last column represents the PCR-positive patients who received effective anti-mold therapy despite the absence of all the EORTC/MSG criteria for diagnosing IA.
deceased patients (mean± SEM= 34.8± 1.2) than in the patients
alive at week 2 (mean± SEM= 38.6± 1.3).
DISCUSSION
The aim of the present study was to improve the specificity
of the GM test by adding on the same tube the detection of
circulating A. fumigatus DNA. We found not only an association
between PCR positivity and the presence of IA, but also for the
first time a quantitative correlation between GM and PCR results
in serum. Moreover, all our results suggest that a PCR-positive
result once GM is already positive is associated with a poorer
prognosis.
Based on the EORTC/MSG classification performed blind to
the PCR results, the percentage of patients with at least one
PCR-positive result increased from 13.2% in the non-IA group
to 63.2% in the IA group (p < 0.0001). However, our results
clearly show that the EORCT/MSG classification does not always
fit with the clinical decision underlining the issue of the GM assay
specificity (Leeflang et al., 2008; Marchetti et al., 2012). Indeed,
among the GM-positive patients, only 18.75% were prescribed
effective anti-mold therapy. Interestingly, 66.7% of the patients
who received antifungal therapy were PCR-positive, and this
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TABLE 2 | Comparison between PCR-positive results and the presence of other
positive microbiological investigation [direct microscopy, culture, and
bronchoalveolar lavage (BAL) GM testing] in 44 patients with probable or proven
invasive aspergillosis and at least one galactomannan (GM) positive sample.
Results of mycological
investigations
PCR-positive
patients
(n = 26) (%)
PCR-negative
patients
(n = 18) (%)
P-value
Serum GM positivity alone 7 (36.8) 12 (63.2) 0.014
Serum GM positivity associated
with other microbiological criteria
19 (76.0) 6 (24.0)
result was not known when the clinical decision was made.
Therefore, PCR performed when GM is already positive can
improve the specificity of the GM result.
We also report for the first time that fungal DNA and GM
titers are positively correlated. In parallel, we observed a higher
mortality at 6 months in hematology when the patients were
PCR-positive. Our hypothesis is that PCR positivity indicates a
more advanced stage of the IA, at least when GM is already
positive. This is also supported by the significant association
of PCR positivity with other microbiological criteria. This
finding is consistent with the poorer prognosis reported when
several mycological criteria are present (Lortholary et al., 2011).
Therefore, if PCR positivity increases the specificity of GM,
this positivity is also associated with a higher fungal load, and
thus, with a poorer prognosis. This finding is also coherent with
the poor prognosis observed when the GM titers remain high
(Boutboul et al., 2002; Nouér et al., 2011; Bergeron et al., 2012).
Although PCR could improve the specificity of some GM-
positive serum samples, many GM-positive samples remain PCR
negative (36.7%), even after the exclusion of unreproducible
GM results (Guigue et al., 2015). We have already observed
more GM-positive than PCR-positive serum samples in different
populations (Bretagne et al., 1998; Millon et al., 2005; Botterel
et al., 2008). Similar findings have been recently reported
(Aguado et al., 2015; Imbert et al., 2016). For instance, less
than 24% of GM-positive patients had at least one PCR-positive
serum sample in a randomized trial (Aguado et al., 2015).
A few of these GM-positive PCR-negative samples could be
related to cross-reactions during infections by other fungi such
as cryptococcosis (Dalle et al., 2005) or histoplasmosis (Rivière
et al., 2012). They can also be due to Aspergillus species not
targeted by the present primers specific for A. fumigatus (Challier
et al., 2004), which represent a very small number of patients
given the high predominance of A. fumigatus among the species
responsible for IA in our patient population (Lortholary et al.,
2011). GM contamination of transfused products and specially
fungus-derived antibiotics are also always a concern, although to
a lesser extend nowadays for piperacillin-tazobactam (Vergidis
et al., 2014).
The main explanation for GM-positive PCR-negative results
is probably the different kinetics of the two biomarkers. In
vitro studies have shown that the maximum release of GM and
A. fumigatus DNA was correlated with increased biomass during
culture, with GM being detectable earlier than DNA (Mennink-
Kersten et al., 2006; Morton et al., 2010). Several animal models
FIGURE 3 | Survival curves according to the presence or not of a
PCR-positive result on GM-positive samples (A), to the presence or not of a
PCR-positive result associated with EORTC/MSG criteria for IA diagnosis (B),
and according to the circulating fungal load as expressed as a Cq value (C).
of pulmonary aspergillosis also showed that GM is detected
earlier, usually 24–48 h before DNA.(Becker et al., 2000; Ahmad
et al., 2014; Lin et al., 2014). Using droplet digital PCR, we
recently showed that the circulating A. fumigatus DNA detected
in patients is fragmented, and we hypothesized that such DNA
comes from dying hyphae, is extracellular and circulates in the
serum (Alanio et al., 2016). Indeed, extracellular DNA has been
detected increasingly over time in a biofilm model of A. fumigatus
and was shown to be produced through autolysis (Rajendran
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et al., 2013). Besides the differences of kinetics between the
two markers during an active IA, other differences may occur.
We observed a lower correlation between GM and DNA when
antifungals are given suggesting a different impact of treatment
on the release of biomarkers in the bloodstream, which warrants
further investigations. This suggests that DNA could be a poorer
marker for following the efficiency of therapy compared to
serum GM (Boutboul et al., 2002; Nouér et al., 2011; Bergeron
et al., 2012). Another reason for discrepancies between GM titers
and PCR Ct may be related to the infecting isolates. Indeed,
possible differences in the copy numbers of the rRNA repeats
(between 61 and 86 copies/genome) chosen as the target for
amplification could affect quantification through PCR according
to the infecting isolate (Alanio et al., 2016).
Our study was not designed to address the issue of a PCR-
positive signal before the onset of GM positivity. In guinea
pigs infected by inhalation, circulating GM antigen was above
the threshold of detection at day 3 and steadily rose thereafter
whereas the PCR assay detected 10 conidial equivalents as soon
as one hour, with a peak of 20 conidial equivalents at 24 h
post infection (Vallor et al., 2008). This observation raises the
issue of the detection of circulating conidia, which are probably
engulfed in macrophages after a pulmonary challenge, either
directly or through dendritic cells as reported for Histoplasma
capsulatum (Lin et al., 2005) and Cryptococcus neoformans
(Lortholary et al., 1999). Aguado et al. (2015) reported PCR-
positive results before GM positivity in 42% of the 30 patients
analyzed, while GM before PCR positivity occurred in 38%.
We have also reported PCR positivity before GM positivity
and concluded that a PCR-positive result accelerates the early
detection of IA independently of the other diagnostic information
(Schwarzinger et al., 2013). Additional specific studies are needed
to determine whether PCR positivity before or after GM positivity
could respond to different pathology processes (detection of
fungal elements vs. circulating DNA). These studies should
nevertheless be difficult to implement given the generalization
of anti-mold prophylaxis. Indeed, some authors suggest that
the potential of PCR to play a decisive role in the diagnosis
and management of IA should be restricted to centers not
applying primary antifungal mold prophylaxis (Springer et al.,
2016).
We acknowledge some limitations to our study due to
the retrospective design. The association between more
microbiological criteria and PCR positivity might be a
consequence of more investigations in patients with a higher
suspicion index. Similarly, the higher mortality observed in
PCR patients with hematological conditions does not mean that
the patients died of IA in light of the difficulties in assessing
the prognosis of IA (Segal et al., 2008). For the PCR protocol,
several criticisms can be addressed. We decided to consider
PCR-positive samples as having a positive threshold of Cq ≤ 45,
and we considered a sample positive even when the duplicate
was not positive. A lower Cq value is often used for censoring
the results when a risk of unspecific positivity is suspected.
For instance, Johnson et al. censored their results at 40 cycles
when using primers and a probe not specifically designed for
A. fumigatus (Johnson et al., 2012). If a threshold of 40 had
been used in our study, 12 samples from 10 patients would have
become PCR negative, restricting the interest of the PCR to very
limited patients with a high fungal DNA load. However, there is
no consensus on the threshold to be used even if ROC analysis
of results of a multicenter study indicated a good diagnostic
accuracy of a Cq ≤ 43 cycles (White et al., 2011). Six patients of
the present study had Cq between ≥43 and ≤45 cycles. One out
these six had a probable IA with A. fumigatus positive culture
from respiratory specimens. Thus, despite the difficulty to obtain
positive duplicates when dealing with low fungal loads (e.g.,
when Cq > 38) because it may be normal to obtain negative
results of replicates according to the Poisson’s law (Alanio and
Bretagne, 2014), we think a Cq≤ 45 should be taken into account
for diagnosing IA for a given patient. The other possibility is to
wait for additional samples and expect a higher fungal load on
the subsequent results to confirm the diagnosis but this attitude
could be deleterious for the patient. Because no systematic
screening of other samples was part of our study restricted to
samples known to be GM-positive, we cannot comment the
benefit to wait for additional samples to improve the specificity
of the PCR results. One can also criticize our choice to focus on
A. fumigatus in light of the increase of other Aspergillus species
in IA (Lionakis et al., 2005) or mixed infections (de Fontbrune
et al., 2014). However, restriction to a specific species decreases
the risk of PCR positivity from environmental non-fumigatus
DNA, especially if high Cq are to be considered (Alanio and
Bretagne, 2014), although contamination with A. fumigatus DNA
cannot be completely excluded (Harrison et al., 2010; Millon
et al., 2010). Moreover, since all the Aspergillus species do not
equally produced GM in the same quantity (Xavier et al., 2013),
quantitative comparison between GM and circulating DNA
would have been biased if a non-A. fumigatus specific PCR had
been used.
CONCLUSION
The diagnosis of IA is a dynamic process where all the diagnostic
elements are not obtained simultaneously. Since prospective
screening is questioned with the generalization of antifungal
prophylaxis in patients at risk of IA, resulting in a decrease in
GM performance (Patterson et al., 2016), GM should become
the first test requested by clinicians in case of febrile pneumonia
for patients at risk of invasive mold infection. Our results clearly
show the added value of PCR tests for every GM-positive serum
sample to increase the probability of IA diagnosis, without
waiting for additional samples. The two markers provide parallel
quantitative information in accordance with the fungal load.
A PCR-positive result is associated with a poorer outcome,
probably as the witness of a higher fungal load, in accordance
with the positivity of the other microbiological investigations.
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